Clinical Trial

Evaluate the Safety of DEXYCU for the Treatment of Inflammation Following Ocular Surgery for Childhood Cataract

Recruiting Phase 4
View on ClinicalTrials.gov →
Record status
This record was last updated April 3, 2025 (before its estimated January 2026 completion). Its status may not reflect the trial's current state.
Summary
A Phase 3/4, Prospective, Randomized, Active Treatment-Controlled, Parallel-Design, Multicenter Study to Evaluate the Safety of DEXYCUfor the Treatment of Inflammation Following Ocular Surgery for Childhood Cataract
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2022-01-03; most recent amendment 2025-04-01.
Trial Details
NCT Number NCT05191706
Lead Sponsor EyePoint Pharmaceuticals, Inc.
Conditions Cataract
Enrollment 60 participants
Start Date 2022-01-04
Primary Completion 2026-01 (estimated)
Study Completion 2026-02 (estimated)
Updated on ClinicalTrials.gov 2025-04-03